


Information Request Email, January 4, 2012 - Hyqvia



From: Maruya, Aiko [Aiko_Maruya@baxter.com]
 Sent: Wednesday, January 04, 2012 11:53 AM
 To: Landow, Laurence; 'aiko.maruya@baxter.com'
 Cc: Shields, Mark
 Subject: RE: IGSC + rHuPH20: Study 170901 part 4

I confirm receipt of the attached message. Aiko

Aiko Maruya, M.S., RAC
 Sr. Manager / Regulatory Affairs
 BioScience
 Baxter Healthcare Corporation
 T (805) 372-3056 direct / Tie-line (b)(4)
 F (805) 372-3052
 aiko_maruya@baxter.com

 

From: Landow, Laurence [mailto:Laurence.Landow@fda.hhs.gov] 
 Sent: Wednesday, January 04, 2012 6:42 AM
 To: 'aiko.maruya@baxter.com'
 Cc: Landow, Laurence; Shields, Mark
 Subject: IGSC + rHuPH20: Study 170901 part 4

Ms. Maruya,

Please submit a schematic indicating Disposition of Subjects for Study 170901 
part 4 as well.

Thank you

Laurence Landow MD, FRCPC
 301.827.6108
 laurence.landow@fda.hhs.gov
 Medical Officer, Clinical Review Branch
 Food and Drug Administration, CBER
 Office of Blood Research & Review
 Division of Hematology
 1401 Rockville Pike
 HFM-392
 Room 425N
 Rockville MD 20852


From:    Landow, Laurence 

Sent:   Wednesday, January 04, 2012 9:31 AM

To:     'aiko.maruya@baxter.com'

Cc:     Shields, Mark; Landow, Laurence

Subject:        IGSC + rHuPH20: Study 161001

Ms. Maruya,

I note that Figure 14.1.1-1 in Final Study Report 160601 and Figure 10.1-1 in 
Final Study Report 160603 present a schematic indicating Disposition of 
Subjects.

Please indicate the page number in Final Study Report 161001 where a similar 
schematic (Figure) can be found. If such a figure is not included in Final Study 
Report 161001, please submit it to the file as soon as possible.

Thank you

Laurence Landow MD, FRCPC
 301.827.6108
 laurence.landow@fda.hhs.gov
 Medical Officer, Clinical Review Branch
 Food and Drug Administration, CBER
 Office of Blood Research & Review
 Division of Hematology
 1401 Rockville Pike
 HFM-392
 Room 425N
 Rockville MD 20852

The information transmitted is intended only for the person(s)or entity to which 
it is addressed and may contain confidential and/or legally privileged material. 
Delivery of this message to any person other than the intended recipient(s) is 
not intended in any way to waive privilege or confidentiality. Any review, 
retransmission, dissemination or other use of , or taking of any action in 
reliance upon, this information by entities other than the intended recipient is 
prohibited. If you receive this in error, please contact the sender and delete 
the material from any computer.

For Translation:

http://www.baxter.com/email_disclaimer
 

    